List of Excipients in Branded Drug DESOXYN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
RECORDATI RARE DISEASES INC	DESOXYN	methamphetamine hydrochloride	55292-102	AMINOBENZOATE SODIUM
RECORDATI RARE DISEASES INC	DESOXYN	methamphetamine hydrochloride	55292-102	LACTOSE
RECORDATI RARE DISEASES INC	DESOXYN	methamphetamine hydrochloride	55292-102	STARCH, CORN
RECORDATI RARE DISEASES INC	DESOXYN	methamphetamine hydrochloride	55292-102	STEARIC ACID
RECORDATI RARE DISEASES INC	DESOXYN	methamphetamine hydrochloride	55292-102	TALC
Key Therapeutics	DESOXYN	methamphetamine hydrochloride	70868-820	AMINOBENZOATE SODIUM

Desoxyn Excipient Strategy and Commercial Opportunities

Last updated: September 5, 2026

Desoxyn is methamphetamine hydrochloride immediate-release tablets, approved in the United States in a 5 mg strength for attention-deficit hyperactivity disorder and short-term weight reduction in selected patients. Its commercial opportunity is primarily off-patent product development, supply reliability, formulation differentiation, and controlled-substance distribution rather than patent exclusivity. The core excipient platform is simple, but any reformulation must preserve rapid release, dose uniformity, tablet integrity, abuse-deterrence considerations, and regulatory compliance.

What is Desoxyn and how is it administered?

Desoxyn contains methamphetamine hydrochloride, a central nervous system stimulant and Schedule II controlled substance. The approved tablet strength is 5 mg. The product is administered orally and is generally titrated according to clinical response and tolerability. The FDA labeling identifies ADHD and short-term adjunctive treatment of exogenous obesity as indications, with limitations on duration and patient selection.[1]

Attribute	Desoxyn
Active ingredient	Methamphetamine hydrochloride
Dosage form	Immediate-release tablet
Approved strength	5 mg
Route	Oral
Drug class	Central nervous system stimulant
Controlled-substance schedule	Schedule II
Primary U.S. indications	ADHD; short-term adjunctive obesity treatment
Reference pathway	NDA product
Commercial product type	Legacy branded prescription drug
Formulation profile	Conventional immediate-release tablet

The product is chemically distinct from amphetamine mixed salts, dextroamphetamine, lisdexamfetamine, and methylphenidate, although all compete within the broader stimulant market.

What excipients are used in Desoxyn tablets?

The Desoxyn label identifies a conventional tablet excipient system that includes corn starch, lactose, magnesium stearate, povidone, and talc.[1] These ingredients support manufacturing performance rather than modified release or specialized delivery.

Excipient	Likely formulation function	Commercial relevance
Corn starch	Disintegrant and filler	Supports rapid tablet breakup and low-cost manufacture
Lactose	Diluent and bulk carrier	Establishes tablet mass and compression behavior
Magnesium stearate	Lubricant	Reduces sticking and ejection force
Povidone	Binder	Improves granule and tablet mechanical strength
Talc	Glidant or anti-adherent	Supports powder flow and manufacturing consistency

The formulation is compatible with a conventional wet-granulation or direct-compression development strategy, subject to excipient grade, powder-flow characteristics, drug loading, and manufacturing equipment.

What excipient risks apply to a Desoxyn generic?

The principal risks are not novel excipient toxicity or complex delivery technology. They are manufacturing and regulatory risks:

• Lactose intolerance or milk-protein sensitivity concerns in specific patient populations.
• Talc quality and elemental impurity controls.
• Magnesium stearate variability affecting dissolution.
• Povidone grade and viscosity effects on granulation.
• Content-uniformity challenges at a 5 mg dose.
• Tablet hardness that delays immediate release.
• Cross-contamination controls for a Schedule II stimulant.

The low dose increases the importance of blend uniformity. A manufacturer should establish validated sampling and segregation controls because the active pharmaceutical ingredient represents a relatively small fraction of total tablet mass.

How should an excipient strategy be designed for Desoxyn?

A commercially credible excipient strategy should preserve the reference product's immediate-release performance while creating operational advantages in supply, manufacturability, patient acceptability, or quality control.

Strategy 1: Reference-like conventional formulation

The lowest-risk approach is to use the labeled excipient classes:

• Lactose as the primary diluent.
• Corn starch as disintegrant.
• Povidone as binder.
• Magnesium stearate as lubricant.
• Talc as processing aid.

This strategy minimizes formulation complexity and supports an ANDA based on pharmaceutical equivalence and bioequivalence. The main development work would involve excipient grade selection, granulation endpoint, compression force, tablet friability, dissolution, and content uniformity.

Strategy 2: Lactose-free formulation

A lactose-free formulation could use microcrystalline cellulose, mannitol, dibasic calcium phosphate, or a combination of these materials. The commercial rationale is broader excipient tolerability and access to patients who avoid lactose-containing products.

A lactose-free product would need to demonstrate that the substitution does not alter:

• Dissolution rate.
• Tablet disintegration.
• Stability.
• Blend uniformity.
• Tablet weight and hardness.
• Bioequivalence.

This strategy may have commercial value, but it would not ordinarily create meaningful patent exclusivity by itself. The opportunity is product positioning, not protection from ANDA competition.

Strategy 3: Direct-compression formulation

Direct compression could reduce processing steps, solvent use, equipment requirements, and manufacturing cost. The main technical issue is achieving acceptable content uniformity at a low active load.

Candidate excipient systems could include:

• Microcrystalline cellulose as filler and compression aid.
• Spray-dried lactose or mannitol for flow.
• Crospovidone or croscarmellose sodium for rapid disintegration.
• Low-substituted hydroxypropyl cellulose as a disintegrant.
• Colloidal silicon dioxide as a glidant.
• Magnesium stearate or sodium stearyl fumarate as lubricant.

A direct-compression product may be attractive for contract manufacturing and decentralized supply, but a significant formulation change can increase bioequivalence and manufacturing-development risk.

Strategy 4: Improved tablet robustness

A robust tablet can reduce breakage during packaging, shipping, and dispensing. This is relevant because Desoxyn is dispensed in controlled quantities and may pass through multiple distribution points.

Potential measures include:

• Optimized binder concentration.
• Higher-performance filler grades.
• Film coating for handling and identification.
• Packaging that limits abrasion and moisture exposure.
• Tight control of compression force and friability.

Film coating should not delay immediate release or create an unnecessary excipient burden. Colorants also create label and patient-sensitivity considerations.

Strategy 5: Abuse-deterrence platform

An abuse-deterrent version could use tamper-resistant matrix technology, aversive excipients, or physical barriers to crushing and extraction. The commercial case is complicated. Desoxyn is an immediate-release tablet and has a small, specialized patient population. Any abuse-deterrence claim would require substantial product-specific evidence under FDA guidance.[2]

An abuse-deterrent formulation could also increase:

• Development cost.
• Manufacturing complexity.
• Tablet size.
• Regulatory review burden.
• Bioequivalence risk.
• Cost of goods.

Without a clear payer or prescriber demand signal, a conventional generic is likely to have a stronger return profile than an expensive abuse-deterrent redesign.

What FDA pathway applies to a Desoxyn generic?

A conventional methamphetamine hydrochloride tablet would generally be developed through the abbreviated new drug application pathway under Section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant would seek to demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug.[3]

The key requirements include:

1. Matching the active ingredient, dosage form, strength, route, and conditions of use.
2. Demonstrating acceptable identity, strength, quality, purity, and stability.
3. Establishing immediate-release dissolution performance.
4. Demonstrating bioequivalence.
5. Addressing labeling and any applicable patent certifications.
6. Obtaining DEA registration and controlled-substance manufacturing authorization.
7. Implementing Schedule II inventory, security, recordkeeping, and distribution controls.

A 505(b)(2) application could be considered for a materially different formulation, such as a novel abuse-deterrent system, new dosage form, or modified clinical use. That route would be more expensive and could generate new regulatory exclusivity or patents, but the commercial case would require a clinically meaningful advantage.

What patents protect Desoxyn and when does Desoxyn lose exclusivity?

Desoxyn is a legacy product. Its original composition, use, and conventional tablet patents, if any, are long expired. The commercial asset is therefore not likely protected by a current, foundational U.S. patent estate.

Exclusivity category	Likely status for Desoxyn
Original composition patent	Expired
Original product patent	Expired
New chemical entity exclusivity	Expired
Current formulation exclusivity	No prominent modern estate identified
Orphan exclusivity	Not applicable to the labeled product
Pediatric exclusivity	No current effect on market access
Conventional generic pathway	Available in principle, subject to FDA and DEA requirements

The FDA Orange Book remains the controlling source for current listed patents, exclusivity codes, and reference-product information.[4] A sponsor should not assume that the absence of a meaningful patent estate eliminates all regulatory barriers. Controlled-substance requirements, reference-product availability, bioequivalence testing, and manufacturing capacity can still delay market entry.

Are there Paragraph IV challenges for Desoxyn?

Paragraph IV litigation is less likely to be commercially significant for a legacy methamphetamine hydrochloride tablet than for a protected branded product. A generic applicant may still need to make the appropriate patent certification if relevant patents appear in the Orange Book. If no unexpired listed patents block approval, the applicant may proceed without a conventional Paragraph IV patent challenge.

The more important question is whether a current listed patent covers a specific formulation, method of use, or other product attribute. Patent risk should be assessed against the current Orange Book entry, not against historical product literature or expired patents.

What formulation patents could create new Desoxyn exclusivity?

A new formulation could generate patentable subject matter if it provides a non-obvious technical result. Potential areas include:

• A controlled-release matrix that changes exposure over time.
• A tamper-resistant tablet with demonstrated resistance to crushing or extraction.
• A multiparticulate formulation with a defined pharmacokinetic profile.
• A low-dose blend with improved content uniformity.
• A lactose-free composition with improved stability or dissolution.
• A taste-masked dosage form for a specific patient population.
• A manufacturing process that materially improves yield or impurity control.
• A novel packaging system combined with product stability or diversion controls.

A simple substitution of lactose with mannitol, or magnesium stearate with another lubricant, would generally face a weak inventive-step position unless the change produced an unexpected result. Stronger patent claims would need to link composition, process parameters, and measurable performance.

What method-of-use patents could apply?

Potential method-of-use claims could target:

• A defined ADHD patient subgroup.
• A specific titration protocol.
• Treatment of a resistant or refractory population.
• A formulation-specific dosing interval.
• A pharmacokinetic strategy intended to reduce misuse or adverse events.

Method-of-use patents face practical limits because generic labels may use carve-outs for patented indications. Their commercial value depends on whether the patented use is central to prescribing and whether the indication can be separated from unpatented uses.

What manufacturing and IP barriers affect commercial entry?

The principal entry barriers are operational rather than patent-based.

Controlled-substance compliance

Methamphetamine hydrochloride is a Schedule II controlled substance. A manufacturer must manage:

• DEA registration.
• Procurement quotas.
• Secure storage.
• Physical security.
• Inventory reconciliation.
• Theft and loss reporting.
• Anti-diversion procedures.
• Controlled distribution records.

These requirements can deter small generic companies even when the formulation itself is simple.[5]

Active pharmaceutical ingredient supply

API sourcing is strategically important. The manufacturer must qualify an API supplier, manage controlled-substance procurement, and maintain adequate inventory without creating excess regulated stock. Supplier concentration can create a larger commercial risk than excipient cost.

Low-volume economics

Desoxyn has a narrower market than mainstream ADHD stimulants. Low unit volume can produce unfavorable economics because fixed costs for DEA compliance, quality systems, stability studies, packaging, and pharmacovigilance are spread across a small number of prescriptions.

Excipient supply

The excipients themselves are widely available. The highest supply risks are likely to involve:

• Consistent pharmaceutical-grade lactose.
• Starch and povidone grade changes.
• Magnesium stearate variability.
• Talc documentation and testing.
• Specialty excipients if a differentiated formulation is developed.

A dual-source strategy for major excipients can reduce manufacturing interruption risk.

How strong is the Desoxyn patent estate?

The patent estate is weak as a barrier to conventional generic entry because the product is old and uses a standard immediate-release tablet platform. Its defensibility would depend on newly developed patents covering a differentiated formulation, manufacturing process, or delivery system.

Estate component	Defensive strength
Active ingredient	Very low
Conventional immediate-release tablet	Very low
Basic excipient substitution	Low
Manufacturing process optimization	Moderate if technically specific
Abuse-deterrent formulation	Moderate to potentially strong
Modified-release delivery	Moderate, subject to clinical and commercial validation
Packaging and diversion controls	Narrow and implementation-dependent
Method-of-use claims	Variable and vulnerable to label carve-out

The commercial value of a new patent estate would depend more on product differentiation and market adoption than on the legacy Desoxyn brand.

What commercial opportunities exist for Desoxyn?

Generic immediate-release tablets

A generic 5 mg tablet is the most direct opportunity. The product could compete on:

• Supply continuity.
• Wholesale acquisition cost.
• Pharmacy availability.
• Reliable controlled-substance fulfillment.
• Contract manufacturing capacity.
• Distributor relationships.

Because the market is specialized, a supply-reliable entrant could gain share even without a novel formulation.

Authorized generic or branded-generic supply

A branded-generic strategy could target institutional pharmacies, specialty distributors, and controlled-substance-focused wholesalers. The value proposition would be product availability and quality consistency rather than clinical differentiation.

Lactose-free or excipient-reduced product

A lactose-free tablet could occupy a limited differentiated niche. The opportunity is most credible if the product is easy to manufacture, has a clear labeling distinction, and avoids a substantial price premium.

Abuse-deterrent product

An abuse-deterrent formulation could support premium pricing or institutional adoption if it demonstrates meaningful resistance to manipulation. The commercial opportunity is uncertain because the patient population is small and the approved product is not positioned as an extended-release stimulant.

International markets

Geographic expansion is constrained by country-specific controlled-substance rules. Methamphetamine is tightly regulated in many jurisdictions, and an indication approved in the United States may not translate directly into foreign registration. The strongest international opportunities would be markets with established stimulant-treatment frameworks and a clear medical need, but each jurisdiction requires separate narcotics, labeling, and import controls.

How does Desoxyn compare with competing ADHD stimulants?

Product category	Active ingredient	Release profile	Market position	Excipient opportunity
Desoxyn	Methamphetamine HCl	Immediate release	Specialized, limited use	Generic supply, lactose-free, abuse deterrence
Adderall IR	Amphetamine salts	Immediate release	Broad ADHD use	Multiple generic competitors
Dexedrine	Dextroamphetamine	Immediate or extended release	Established stimulant	Generic and extended-release competition
Vyvanse	Lisdexamfetamine	Prodrug, extended effect	Premium branded and generic competition	Prodrug and delivery-related differentiation
Concerta	Methylphenidate	Extended release	Broad ADHD use	Delivery-system and release-profile protection
Ritalin IR	Methylphenidate	Immediate release	Mature generic market	Cost and supply competition

Desoxyn has a narrower clinical and commercial footprint. Its advantage for a manufacturer is formulation simplicity. Its disadvantage is limited demand and the operational burden of handling a Schedule II stimulant.

What revenue exposure and launch scenarios should investors consider?

The main financial variables are prescription volume, reimbursement, API availability, and generic competition. A launch can follow three broad scenarios:

Scenario	Product strategy	Commercial result
Low-cost generic	Reference-like 5 mg tablet	Fastest route, low differentiation, price pressure
Supply-reliable niche product	Conventional tablet with strong inventory controls	Potential share capture during shortages or discontinuations
Premium differentiated product	Lactose-free, abuse-deterrent, or modified-release formulation	Higher development cost and regulatory risk, potentially higher pricing

A single generic entrant may benefit from limited competition, but additional entrants can rapidly compress pricing. The product's small market size limits the attractiveness of high-cost clinical or formulation programs unless the sponsor has an existing controlled-substance platform.

What litigation and settlement issues affect Desoxyn?

No major modern patent-litigation pattern defines the conventional Desoxyn tablet market. Litigation risk would become more relevant if a sponsor introduced:

• A new extended-release formulation.
• An abuse-deterrent product.
• A patented manufacturing process.
• A method-of-use product with commercial promotion.
• A branded-generic arrangement involving supply or distribution rights.

Settlement agreements would need review for launch timing, authorized-generic provisions, supply obligations, and antitrust risk. The absence of a large legacy patent estate makes a classic branded-versus-generic settlement less likely than supply, licensing, or manufacturing agreements.

Key Takeaways

• Desoxyn is a 5 mg immediate-release methamphetamine hydrochloride tablet.
• Its labeled excipients are conventional: corn starch, lactose, magnesium stearate, povidone, and talc.
• The most practical formulation strategy is a reference-like generic tablet.
• A lactose-free formulation offers modest differentiation without necessarily creating strong patent protection.
• Abuse-deterrent and modified-release products could create new IP but require substantially greater development investment.
• The legacy patent estate is weak as a barrier to generic entry.
• DEA compliance, API sourcing, controlled distribution, and low market volume are the main commercial constraints.
• The strongest near-term opportunity is reliable generic supply, not a high-cost reformulation.
• FDA Orange Book status, current reference-product designation, and controlled-substance requirements must determine launch timing and patent-certification strategy.

FAQs About Desoxyn Excipient and Commercial Strategy

Is Desoxyn lactose-free?

No. The FDA labeling identifies lactose among the inactive ingredients in the conventional Desoxyn tablet.[1]

Can a generic Desoxyn use different excipients?

Yes. A generic may use different inactive ingredients if it meets applicable FDA requirements for pharmaceutical equivalence, bioequivalence, quality, stability, and labeling.

Is methamphetamine hydrochloride difficult to manufacture?

The tablet formulation is technically simple, but manufacture is operationally complex because methamphetamine hydrochloride is a Schedule II controlled substance. DEA registration, quotas, security, inventory controls, and anti-diversion procedures are required.

Would a lactose-free Desoxyn automatically receive patent protection?

No. Replacing lactose with another diluent would not automatically create patentable subject matter. Patentability would depend on novelty, non-obviousness, and a demonstrated technical advantage.

Is an extended-release Desoxyn commercially attractive?

It could create product differentiation, but the development burden would be substantially higher than for an immediate-release generic. The sponsor would need to establish a defensible pharmacokinetic profile, clinical utility, manufacturing reproducibility, and regulatory pathway.

References

1. U.S. Food and Drug Administration. (2023). Desoxyn (methamphetamine hydrochloride) tablets, prescribing information. FDA-approved labeling.

2. U.S. Food and Drug Administration. (2015). General principles for evaluating abuse-deterrent properties of proprietary opioid drug products: Guidance for industry. FDA.

3. U.S. Food and Drug Administration. (2024). Abbreviated new drug application (ANDA) process. FDA.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

5. U.S. Drug Enforcement Administration. (2024). Controlled substances act and DEA regulations for Schedule II controlled substances. U.S. Department of Justice.